Dry Eye Syndrome Market Size, Share and Trends Analysis by Region, Product (Anti-inflammatory Drugs, Artificial Tears, Punctal Plugs, Secretagogues), Therapy Area (Eye drops and Solutions, Gels and Ointments, Capsules and Tablets), Distribution Channel and Segment Forecast, 2022-2027

Pages: 121 Published: November 22, 2022 Report Code: GDPH-SC-MR007

The dry eye syndrome market size was valued at US$ 5.46 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 4.8% during 2022-2027. The major factors contributing to the market growth includes, rise in ageing population and growth in eye care centers to handle the rising burden of ophthalmological disorders. However, factors such as the availability of alternative therapies may hinder the market in focus growth. On contrary, increasing public-private initiatives leading to early diagnosis and treatment of dry eye syndrome and growing prevalence of dry eye syndrome will boost the dry eye syndrome market growth.

Dry Eye Syndrome Market Overview

Dry Eye Syndrome Market Overview

View Sample Report for Additional Insights on the Dry Eye Syndrome Market Forecast, Download a Free Report Sample

Several causes, including age, declining supporting hormones, systemic inflammatory disorders, ocular surface diseases, and procedures that impact the cholinergic neurons that drive tear production, may be linked to the increased occurrence of dry eye-related diseases. The world’s expanding geriatric population is likely to be a significant driver for the market, as the elderly’s eyes produce fewer tears, resulting in greater evaporation and dryness. Furthermore, the emergence of high-risk steroids such as Lotemax has pushed clinicians to take these drugs for extended periods of time. Continuing research aims to get a more complete understanding of inflammatory pathways and to target several types of inflammatory mediators in dry eye patients.

Dry Eye Syndrome Market Segmentation by Product

The dry eye syndrome can be segmented into anti-inflammatory drugs, artificial tears, punctal plugs, and secretagogues based on product.

Ophthalmic anti-inflammatory drugs are a group of medications that are used to treat inflammatory eye conditions, such as allergic conjunctivitis, dry eye syndrome, non-infectious uveitis, and to treat eye inflammation after an ophthalmic surgery or procedure. Cyclosporine is one of the most commonly used anti-inflammatory drug used in dry eye syndrome. Cyclosporine eye drops aid in increasing tear production in patients whose tear production is supposed to be blocked owing to ocular inflammation linked with keratoconjunctivitis sicca or dry eye. For a variety of causes, tear production may be insufficient and unstable, but this instability can result in discomfort, irritation, and even potential surface damage to the eye.

Dry Eye Syndrome Market Share by Product, 2021 (%)

Dry Eye Syndrome Market Share by Product, 2021 (%)

Fetch Sample PDF for Segment-Specific Revenues and Shares, Download a Free Report Sample

Dry Eye Syndrome Market Segmentation by Dosage Form

The dry eye syndrome can be segmented into eye drops and solutions, gels and ointments, and capsules and tablets based on dosage form.

The standard course of treatment for dry eye and other similar disorders is eye drops. Preservative or preservative-free, contact lens friendly, standard, and cross-linked Hyaluronic Acid drops are just a few of the many varieties available. Most eye conditions, such as dry eyes, pink eye, red eyes, or itching, can be treated with eye drops. Depending on the symptoms, one can decide which kind of eye drops will work best for oneself. The following eye symptoms, including dryness, redness, itching, pain, swelling, and discharge, can be relieved with eye drops.

Artificial tears or lubricating eye drops can temporarily relieve dry eyes. When addressing dry eye caused by computer eye strain, being outdoors in windy and sunny weather, fatigue, or other transient issues, these drops work well. When compared to utilizing eye drops with additions that are unnatural to the tears, most over-the-counter lubricating eye drops have additional ingredients that are already present in your natural tears.

Dry Eye Syndrome Market Share by Dosage Form, 2021 (%)

Dry Eye Syndrome Market Share by Dosage Form, 2021 (%)

Fetch Sample PDF for Segment-Specific Revenues and Shares, Download a Free Report Sample

Dry Eye Syndrome Market Analysis by Region

North America led the dry eye syndrome market in 2021, owing to its high prevalence of dry eye diseases and the easy accessibility to treatments in the region. In this multi-screen universe, individuals of all ages may be found to be affected with dry eye issues. Computer or digital screen usage may result in less blinking, which may lead to symptoms of dry eye illness, raising the demand for better and more effective disease therapies, which is predicted to fuel expansion of the market. Furthermore, the region’s ageing population is driving market expansion since they are more susceptible to ocular ailments such as dry eye syndrome.

Dry Eye Syndrome Market Share by Region, 2021 (%)

Dry Eye Syndrome Market Share by Region, 2021 (%)

View Sample Report for Additional Dry Eye Syndrome Market Insights, Download a Free Report Sample

Dry Eye Syndrome Market - Competitive Landscape

Key players operating in the dry eye syndrome market are more focused on organic growth strategies like new product launches and enhancement of existing products, to improve their competitive position and gain further market share. For instance, in October 2022, Health Canada approved Santen Canada Inc’s, a subsidiary of Santen Pharmaceutical Co. Ltd., Cationorm Plus. Cationorm Plus is an exclusive hydrating artificial tear that reinstates moisture in the eye to deliver long-lasting relief for dry eye indications.

Leading Players in the Dry Eye Syndrome Market

  • Novartis AG
  • AbbVie Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Johnson & Johnson Services Inc.
  • RegeneRx Biopharmaceuticals Inc.
  • Santen Pharmaceutical Co. Ltd.
  • AFT Pharmaceuticals Pty Ltd.
  • Viatris Inc.
  • Other major players

Other Dry Eye Syndrome Market Vendors Mentioned

Novaliq GmbH, Oculis S.A., Yumanity Therapeutics Inc., ThermaMEDx LLC, Oasis Medical, Oyster Point Pharma Inc., among others

To Know More About Dry Eye Syndrome Market Players, Download a Free Report Sample

Dry Eye Syndrome Market Research Overview

Market Size (2021) US$ 5.46 billion
Market Size (2027) US$ 7.22 billion
CAGR 4.8%
Forecast Period 2022-2027
Historic Period 2020-2021
Report Scope & Coverage Revenue Forecast, Segmental Market Share, Trends, Drivers, and Challenges, Segmental Forecast, Pipeline Products
Product Segment Anti-inflammatory Drugs, Artificial Tears, Punctal Plugs, Secretagogues
Dosage Form Segment Eye Drops and Solutions, Gels and Ointments, Capsules and Tablets
Distribution Channel Segment Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Key Companies Novartis AG, AbbVie Inc., Sun Pharmaceutical Industries Ltd., Johnson & Johnson Services Inc., RegeneRx Biopharmaceuticals Inc., Bausch Health Companies Inc., Santen Pharmaceutical Co. Ltd., AFT Pharmaceuticals Pty Ltd., Viatris Inc.

Dry Eye Syndrome Market Scope

GlobalData Plc has segmented the dry eye syndrome market report by product, dosage form, distribution channel and region:

Dry Eye Syndrome Product Outlook (Revenue, USD Million, 2020-2027)

  • Anti-inflammatory Drugs
  • Artificial Tears
  • Punctal Plugs
  • Secretagogues 

Dry Eye Syndrome Dosage Form Outlook (Revenue, USD Million, 2020-2027)

  • Eye Drops and Solutions
  • Gels and Ointments
  • Capsules and Tablets

Dry Eye Syndrome Distribution Channel Outlook (Revenue, USD Million, 2020-2027)

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Dry Eye Syndrome Regional Outlook (Revenue, USD Million, 2020-2027)

  • North America
  • US
  • Canada
  • Europe 
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia Pacific 
  • China
  • Japan
  • India
  • Rest of Asia Pacific
  • ROW

The market intelligence report provides an in-depth analysis of the following –

  • Dry eye syndrome market outlook: analysis as well as historical figures and forecasts of revenue opportunities from the product, dosage form, and distribution channel segments
  • The competitive landscape: an examination of the positioning of leading players in the dry eye syndrome market
  • Company snapshots: analysis of the market position of leading players in the dry eye syndrome market

Reasons to Buy

  • This market intelligence report offers a thorough, forward-looking analysis of the global dry eye syndrome market and key opportunities in a concise format to help executives build proactive and profitable growth strategies
  • Accompanying GlobalData’s Forecast products, the report examines the assumptions and drivers behind ongoing and upcoming trends in dry eye syndrome market
  • The report also highlights key product, dosage form, and distribution channel segments
  • With different charts and tables, the report is designed for an executive-level audience, boasting presentation quality
  • The report provides an easily digestible market assessment for decision-makers built around in-depth information gathered from market players, which enables executives to quickly get up to speed with the current and emerging trends in dry eye syndrome market

Key Players

Novartis AG
AbbVie Inc.
Sun Pharmaceutical Industries Ltd.
Johnson & Johnson Services Inc.
REGENERX BIOPHARMACEUTICALS INC.
Bausch Health Companies Inc.
SANTEN PHARMACEUTICAL CO. LTD.
AFT Pharmaceuticals Pty Ltd.
VIATRIS INC.

Table of Contents

CHAPTER 01 Executive Summary

1.1 Dry Eye Syndrome Market Snapshot

Fig.1 Market Snapshot ($Mn)

1.2 Dry Eye Syndrome Market- Key Findings

Fig.2 Key Segment Performance Snapshot

CHAPTER 02 Market Landscape

2.1 Market Definition

2.1.1 Risk Factors and Comorbidities

Fig.3 Risk Factors and Comorbidities for DES

2.1.2 Disease Classification

Fig.4 Risk Factors and Comorbidities for DES

2.2 Market Scope and Segmentation

CHAPTER 03 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Etiology

Fig.5 Vicious Circle of Dry Eye Syndrome

3.1.2 Pathophysiology

3.2 Epidemiological For Dry Eye Syndrome

3.2.1 Age-Specific Diagnosed Prevalent Cases of Dry Eye Syndrome

3.2.2 Sex-Specific Diagnosed Prevalent Cases of Dry Eye Syndrome

3.2.3 Diagnosed Prevalent Cases of Dry Eye Syndrome by Severity

3.2.4 Total Prevalent Cases of Dry Eye Syndrome

CHAPTER 04 Disease Management

4.1 Diagnosis and Treatment Overview

4.1.1 Diagnosis

Fig.6 Diagnostic Tests for Dry Eye Syndrome

4.1.2 Treatment Guidelines

Fig.7 Treatment Guidelines for Dry Eye Syndrome

4.1.3 Clinical Practice

Fig.8 Country Profile – US

Fig.9 Country Profile – 5EU

Fig.10 Country Profile – Japan

Fig.11 Country Profile – India

CHAPTER 05 Competitive Assessment

5.1 Cyclosporine

5.2 LFA-1 Antagonist

5.3 Mucin Secretagogue

5.4 Corticosteroids

5.5 Artificial Tears

5.6 Autologous Serum

CHAPTER 06 Unmet Needs and Opportunity Assessment

6.1 Overview

Fig.12 Unmet Needs and Opportunities in Dry Eye Syndrome

6.2 More Treatment Options with Favorable Tolerability Profiles

6.3 Better Diagnostic Tools

6.4 Simplified Dosing with Cost-Effective Options

Fig.13 : Products in Clinical Development for Dry Eye Syndrome

CHAPTER 07 Pipeline Assessment

7.1 Overview

7.2 Late-Stage Pipeline Products

Fig.14 : Key Phase IIb/III Trials for the Promising Pipeline Agents that GlobalData Expects be Licensed for Dry eye Syndrome in the Major Markets

CHAPTER 08 Dry Eye Syndrome Industry Analysis

8.1 Dry Eye Syndrome Market Structure – PORTER’s Analysis

Fig.15 Global Dry Eye Syndrome PORTER’s Five Force Analysis

8.2 Product Launches in Dry Eye Syndrome

8.3 Important Milestones in Dry Eye Syndrome

CHAPTER 09 Global Dry Eye Syndrome Revenue Opportunity

9.1 Global Dry Eye Syndrome Market

Fig.16 Global Dry Eye Syndrome Market – Revenue Opportunity Forecast, 2020-2027 ($Mn)

CHAPTER 010 Dry Eye Syndrome Product Outlook

10.1 Dry Eye Syndrome – Product Dive

Fig.17 Dry Eye Syndrome by Product – Market Overview ($Mn)

Fig.18 Dry Eye Syndrome by Product Share – 2021 & 2027 (%)

10.1.1 Anti-inflammatory Drugs

Fig.19 Anti-inflammatory Drugs Market Revenue Opportunity Forecast, 2020-2027 ($Mn)

10.1.2 Artificial Tears

Fig.20 Artificial Tears Market Revenue Opportunity Forecast, 2020-2027 ($Mn)

10.1.3 Punctal Plugs

Fig.21 Punctal Plugs Market Revenue Opportunity Forecast, 2020-2027 ($Mn)

10.1.4 Secretagogues

Fig.22 Secretagogues Market Revenue Opportunity Forecast, 2020-2027 ($Mn)

CHAPTER 011 Dry Eye Syndrome Dosage Form Outlook

11.1 Dry Eye Syndrome –Dosage Form Dive

Fig.23 Dry Eye Syndrome by Dosage Form – Market Overview ($Mn)

Fig.24 Dry Eye Syndrome by Dosage Form Share – 2021 & 2027 (%)

11.1.1 Eye Drops and Solutions

Fig.25 Eye Drops and Solutions Market Revenue Opportunity Forecast, 2020-2027 ($Mn)

11.1.2 Gels and Ointments

Fig.26 Gels and Ointments Market Revenue Opportunity Forecast, 2020-2027 ($Mn)

11.1.3 Capsules and Tablets

Fig.27 Capsule and Tablets Market Revenue Opportunity Forecast, 2020-2027 ($Mn)

CHAPTER 012 Dry Eye Syndrome Distribution Channel Outlook

Fig.28 Dry Eye Syndrome by Distribution Channel – Market Overview ($Mn)

Fig.29 Dry Eye Syndrome by Distribution Channel Share – 2021 & 2027 (%)

12.1.1 Hospital Pharmacy

Fig.30 Hospital Pharmacy -Market Revenue Opportunity Forecast, 2020-2027 ($Mn)

12.1.2 Retail Pharmacy

Fig.31 Retail Pharmacy Market Revenue Opportunity Forecast, 2020-2027 ($Mn)

12.1.3 Online Pharmacy

Fig.32 Online Pharmacy Market Revenue Opportunity Forecast, 2020-2027 ($Mn)

CHAPTER 013 Dry Eye Syndrome by Regional Outlook

13.1 Dry Eye Syndrome – Regional Deep Dive

Fig.33 Dry Eye Syndrome by Region– Market Overview ($Mn)

Fig.34 Dry Eye Syndrome by Region Share – 2021 & 2027 (%)

13.1.1 North America

Fig.35 North America Market Revenue Opportunity Forecast, 2020-2027 ($Mn)

13.1.2 Europe

Fig.36 Europe Market Revenue Opportunity Forecast, 2020-2027 ($Mn)

13.1.3 Asia-Pacific

Fig.37 Asia-Pacific Market Revenue Opportunity Forecast, 2020-2027 ($Mn)

13.1.4 ROW

Fig.38 ROW Market Revenue Opportunity Forecast, 2020-2027 ($Mn)

CHAPTER 014 Trends, Drivers, and Challenges

14.1 Dry Eye Syndrome – Market Trends

14.1.1 Increasing public-private initiatives leading to early diagnosis and treatment of dry eye syndrome

14.1.2 Growing prevalence of dry eye syndrome

14.2 Dry Eye Syndrome – Market Drivers

14.2.1 Rise in Ageing Population

14.2.2 Growth in eye care centers to handle the Rising burden of ophthalmological disorders

14.2.3 Increasing Research & Development and promising pipeline products

14.3 Dry Eye Syndrome – Market Challenges

14.3.1 High cost of specialty dry eye products

14.3.2 Alternative therapies

14.4 Dry Eye Syndrome – Market Opportunities

14.4.1 Demand for therapies with enhanced delivery systems

14.4.2 Creating Appropriate Clinical Trial Design

CHAPTER 015 Current and Future Players

15.1 Allergan

Fig.39 Allergan’s Dry Eye Syndrome Portfolio Assessment

15.2 Aldeyra Therapeutics

Fig.40 Allergan’s Dry Eye Syndrome Portfolio Assessment

15.3 Aurinia Pharmaceuticals

Fig.41 Aurinia’s Dry Eye Syndrome Portfolio Assessment

15.4 Kala Pharmaceuticals

Fig.42 Kala’s Dry Eye Syndrome Portfolio Assessment

15.5 Mitotech

Fig.43 Mitotech’s Dry Eye Syndrome Portfolio Assessment

15.6 Novartis

Fig.44 Novartis Dry Eye Syndrome Portfolio Assessment

15.7 RegeneRX Biopharmaceuticals/ReGenTree

Fig.45 Novartis Dry Eye Syndrome Portfolio Assessment

15.8 Sun Pharmaceutical

Fig.46 Sun’s Dry Eye Syndrome Portfolio Assessment

CHAPTER 016 Competitive Landscape

16.1.1 Heat Map Analysis

16.1.2 Key Players strategy Outlook

16.1.3 Recent Product Launches & approvals

16.1.4 Recent partnerships, alliances, collaborations

CHAPTER 017 Dry Eye Syndrome Market Vendor Snapshot

17.1.1 Company snapshot: Novartis AG

17.1.2 Company snapshot: AbbVie Inc.

17.1.3 Company snapshot: Sun Pharmaceutical Industries Ltd.

17.1.4 Company snapshot: Johnson & Johnson Services Inc.

17.1.5 Company snapshot: RegeneRx Biopharmaceuticals Inc.

17.1.6 Company snapshot: Bausch Health Companies Inc.

17.1.7 Company snapshot: Santen Pharmaceutical Co. Ltd.

17.1.8 Company snapshot: AFT Pharmaceuticals Pty Ltd.

17.1.9 Company snapshot: Viatris Inc.

17.1.10 Company snapshot: Alcon Inc.

17.1.11 Other Major Participants in the Dry Eye Syndrome Market include the following

CHAPTER 018 Appendix

18.1 Methodology

18.2 About US

Contact Us

List of Tables

Table 1 Key Trends, Drivers, and Challenges Overview

Table 2 Research Scope and Segmentation

Table 3 Comparison of Therapeutic Classes in Development for DES

Table 4 Product Launches in Dry Eye Syndrome

Table 5 Important Milestones in Dry Eye Syndrome

Table 6 Dry Eye Syndrome Market

Table 7 Dry Eye Syndrome by Product, 2020-2027 ($Mn)

Table 8 Dry Eye Syndrome by Dosage Form, 2020-2027 ($Mn)

Table 9 Dry Eye Syndrome by Distribution Channel, 2020-2027 ($Mn)

Table 10 Dry Eye Syndrome by Region, 2020-2027 ($Mn)

Table 11 North America Dry Eye Syndrome by Country, 2020-2027 ($Mn)

Table 12 Europe Dry Eye Syndrome by Country, 2020-2027 ($Mn)

Table 13 Asia-Pacific Dry Eye Syndrome by Country, 2020-2027 ($Mn)

List of Figures

Fig.1 Market Snapshot ($Mn)

Fig.2 Key Segment Performance Snapshot

Fig.3 Risk Factors and Comorbidities for DES

Fig.4 Risk Factors and Comorbidities for DES

Fig.5 Vicious Circle of Dry Eye Syndrome

Fig.6 Diagnostic Tests for Dry Eye Syndrome

Fig.7 Treatment Guidelines for Dry Eye Syndrome

Fig.8 Country Profile – US

Fig.9 Country Profile – 5EU

Fig.10 Country Profile – Japan

Fig.11 Country Profile – India

Fig.12 Unmet Needs and Opportunities in Dry Eye Syndrome

Fig.13 : Products in Clinical Development for Dry Eye Syndrome

Fig.14 : Key Phase IIb/III Trials for the Promising Pipeline Agents that GlobalData Expects be Licensed for Dry eye Syndrome in the Major Markets

Fig.15 Global Dry Eye Syndrome PORTER’s Five Force Analysis

Fig.16 Global Dry Eye Syndrome Market – Revenue Opportunity Forecast, 2020-2027 ($Mn)

Fig.17 Dry Eye Syndrome by Product – Market Overview ($Mn)

Fig.18 Dry Eye Syndrome by Product Share – 2021 & 2027 (%)

Fig.19 Anti-inflammatory Drugs Market Revenue Opportunity Forecast, 2020-2027 ($Mn)

Fig.20 Artificial Tears Market Revenue Opportunity Forecast, 2020-2027 ($Mn)

Fig.21 Punctal Plugs Market Revenue Opportunity Forecast, 2020-2027 ($Mn)

Fig.22 Secretagogues Market Revenue Opportunity Forecast, 2020-2027 ($Mn)

Fig.23 Dry Eye Syndrome by Dosage Form – Market Overview ($Mn)

Fig.24 Dry Eye Syndrome by Dosage Form Share – 2021 & 2027 (%)

Fig.25 Eye Drops and Solutions Market Revenue Opportunity Forecast, 2020-2027 ($Mn)

Fig.26 Gels and Ointments Market Revenue Opportunity Forecast, 2020-2027 ($Mn)

Fig.27 Capsule and Tablets Market Revenue Opportunity Forecast, 2020-2027 ($Mn)

Fig.28 Dry Eye Syndrome by Distribution Channel – Market Overview ($Mn)

Fig.29 Dry Eye Syndrome by Distribution Channel Share – 2021 & 2027 (%)

Fig.30 Hospital Pharmacy -Market Revenue Opportunity Forecast, 2020-2027 ($Mn)

Fig.31 Retail Pharmacy Market Revenue Opportunity Forecast, 2020-2027 ($Mn)

Fig.32 Online Pharmacy Market Revenue Opportunity Forecast, 2020-2027 ($Mn)

Fig.33 Dry Eye Syndrome by Region– Market Overview ($Mn)

Fig.34 Dry Eye Syndrome by Region Share – 2021 & 2027 (%)

Fig.35 North America Market Revenue Opportunity Forecast, 2020-2027 ($Mn)

Fig.36 Europe Market Revenue Opportunity Forecast, 2020-2027 ($Mn)

Fig.37 Asia-Pacific Market Revenue Opportunity Forecast, 2020-2027 ($Mn)

Fig.38 ROW Market Revenue Opportunity Forecast, 2020-2027 ($Mn)

Fig.39 Allergan’s Dry Eye Syndrome Portfolio Assessment

Fig.40 Allergan’s Dry Eye Syndrome Portfolio Assessment

Fig.41 Aurinia’s Dry Eye Syndrome Portfolio Assessment

Fig.42 Kala’s Dry Eye Syndrome Portfolio Assessment

Fig.43 Mitotech’s Dry Eye Syndrome Portfolio Assessment

Fig.44 Novartis Dry Eye Syndrome Portfolio Assessment

Fig.45 Novartis Dry Eye Syndrome Portfolio Assessment

Fig.46 Sun’s Dry Eye Syndrome Portfolio Assessment

Frequently Asked Questions

The dry eye syndrome market size was valued at US$ 5.46 billion in 2021.

The dry eye syndrome market is expected to grow at a CAGR of 4.8% during the forecast period (2022-2027).

Rise in ageing population, growth in eye care centers to handle the rising burden of ophthalmological disorders, and increasing research and development are some of the major factors fueling dry eye syndrome market growth.

  • Product: Anti-inflammatory Drugs, Artificial Tears, Punctal Plugs, Secretagogues
  • Dosage Form: Eye Drops and Solutions, Gels and Ointments, Capsules and Tablets
  • Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Some of the leading companies in the dry eye syndrome market are Novartis AG, AbbVie Inc., Sun Pharmaceutical Industries Ltd., Johnson & Johnson Services Inc.

$3,950

Can be used by individual purchaser only

$7,950

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about our multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Testimonial

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods
Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.

Keratoconjunctivitis Sicca (Dry Eye)
New
Diabetic Foot Ulcers Treatment Market Size, Share and Trends Analysis…
$3,950 | November 2022
Keratoconjunctivitis Sicca (Dry Eye)
New
Dry Eye Syndrome Market Size, Share and Trends Analysis by…
$3,950 | November 2022
Keratoconjunctivitis Sicca (Dry Eye)
New
Non-Small Cell Lung Cancer Marketed and Pipeline Drugs Assessment, Clinical…
$3,495 | November 2022